Log in Register
Menu

Anti-Cisplatin modified DNA [CP9/19]

Info

Catalogue Number 151464
Applications ELISA FACS IHC IP DB
Antigen/Gene or Protein Targets Cisplatin modified native DNA
Reactivity N/A
Relevance This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
Host Rat
Immunogen Cisplatin modified native DNA
Subclass IgG2a
Positive Control RNA/DNA
Myeloma Used Y3.AG.1.2.3
Recommended Growing Conditions DMEM + 10%FCS + Glu + Pen/Strep
Notes Alternative Name: ICR4
Research Area DNA Damage and Repair, Epigenetics & Nuclear Signalling

References: 14 entries

Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.

IP

Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.

Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.

Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.

Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.

Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.

Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.

Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.

Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.

Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.

Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.


Add a reference


This reagent does not have any reviews at the moment.